EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2017
At a glance
- Drugs EC 18 (Primary)
- Indications Febrile neutropenia
- Focus Proof of concept; Therapeutic Use
- Sponsors Enzychem Lifesciences Corporation
- 08 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Nov 2017.
- 19 Jun 2017 Status changed from not yet recruiting to recruiting according to a Enzychem Lifesciences Corp. media release.
- 01 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jun 2017.